Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.
Adolescent
Adult
Aged
COVID-19
/ complications
Child
Child, Preschool
Europe
/ epidemiology
Female
Humans
Infant
Kidney Failure, Chronic
/ complications
Kidney Transplantation
/ mortality
Male
Middle Aged
Pandemics
Postoperative Complications
/ mortality
Registries
Renal Dialysis
Risk Factors
Young Adult
COVID-19
attributable mortality
dialysis
kidney replacement therapy
registries
transplantation
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
25
06
2020
revised:
01
09
2020
accepted:
03
09
2020
pubmed:
27
9
2020
medline:
22
12
2020
entrez:
26
9
2020
Statut:
ppublish
Résumé
The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined the role of patient characteristics, treatment factors, and country on mortality risk with the use of ERA-EDTA Registry data on patients receiving kidney replacement therapy in Europe from February 1, 2020, to April 30, 2020. Additional data on all patients with a diagnosis of COVID-19 were collected from 7 European countries encompassing 4298 patients. COVID-19-attributable mortality was calculated using propensity score-matched historic control data and after 28 days of follow-up was 20.0% (95% confidence interval 18.7%-21.4%) in 3285 patients receiving dialysis and 19.9% (17.5%-22.5%) in 1013 recipients of a transplant. We identified differences in COVID-19 mortality across countries, and an increased mortality risk in older patients receiving kidney replacement therapy and male patients receiving dialysis. In recipients of kidney transplants ≥75 years of age, 44.3% (35.7%-53.9%) did not survive COVID-19. Mortality risk was 1.28 (1.02-1.60) times higher in transplant recipients compared with matched dialysis patients. Thus, the pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy, a highly vulnerable population due to underlying chronic kidney disease and a high prevalence of multimorbidity.
Identifiants
pubmed: 32979369
pii: S0085-2538(20)31081-4
doi: 10.1016/j.kint.2020.09.006
pmc: PMC7560263
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1540-1548Informations de copyright
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
JAMA. 2009 Oct 28;302(16):1782-9
pubmed: 19861670
Kidney Int. 2020 Jun;97(6):1074-1075
pubmed: 32354635
J Am Soc Nephrol. 2020 Jun;31(6):1150-1156
pubmed: 32317402
Clin J Am Soc Nephrol. 2011 Jul;6(7):1722-30
pubmed: 21734088
J Am Soc Nephrol. 2020 Jul;31(7):1409-1415
pubmed: 32467113
Nefrologia. 2020 May - Jun;40(3):272-278
pubmed: 32389518
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Kidney Int. 2020 Jul;98(1):20-26
pubmed: 32437768
Kidney Int. 2020 Jul;98(1):27-34
pubmed: 32437770
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Kidney Int. 2020 Jun;97(6):1076-1082
pubmed: 32354637
G Ital Nefrol. 2020 Apr 9;37(2):
pubmed: 32281756
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Am J Kidney Dis. 2020 Jul;76(1):141-143
pubmed: 32240718